Prospective, double blinded, comparative assessment of the pharmacological activity of Cerebrolysin and distinct peptide preparations for the treatment of embolic stroke.

Zhang, Li et al.·Journal of the neurological sciences·2019·
RPEP-045912019RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Prospective, double blinded, comparative assessment of the pharmacological activity of Cerebrolysin and distinct peptide preparations for the treatment of embolic stroke.
Published In:
Journal of the neurological sciences, 398, 22-26 (2019)
Database ID:
RPEP-04591

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-04591·https://rethinkpeptides.com/research/RPEP-04591

APA

Zhang, Li; Chopp, Michael; Wang, Chunyang; Zhang, Yi; Lu, Mei; Zhang, Talan; Zhang, Zheng Gang. (2019). Prospective, double blinded, comparative assessment of the pharmacological activity of Cerebrolysin and distinct peptide preparations for the treatment of embolic stroke.. Journal of the neurological sciences, 398, 22-26. https://doi.org/10.1016/j.jns.2019.01.017

MLA

Zhang, Li, et al. "Prospective, double blinded, comparative assessment of the pharmacological activity of Cerebrolysin and distinct peptide preparations for the treatment of embolic stroke.." Journal of the neurological sciences, 2019. https://doi.org/10.1016/j.jns.2019.01.017

RethinkPeptides

RethinkPeptides Research Database. "Prospective, double blinded, comparative assessment of the p..." RPEP-04591. Retrieved from https://rethinkpeptides.com/research/zhang-2019-prospective-double-blinded-comparative

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.